Taiwan Liposome gains dual listing with NASDAQ offering

Taiwan Liposome Co. Ltd. (TPEx:4152; NASDAQ:TLC) raised $21.8 million in a NASDAQ listing on Nov. 21. Although the biotech raised less than it had proposed, it gained a dual listing it hopes will provide access to investors who will better recognize the company's value.

The drug delivery company had originally proposed in February to raise $50 million on NASDAQ after finding the Taiwanese market inhospitable to biotech. It later amended its proposal this month to raise a maximum of $33.4 million (see "Seeking Maturity")...